Minerva Neurosciences (NERV) Change in Account Payables (2014 - 2026)

Minerva Neurosciences (NERV) has 13 years of Change in Account Payables data on file, last reported at $1.5 million in Q1 2026.

• Quarterly Change in Account Payables rose 251.37% year-over-year to $1.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.4 million (up 272.69% YoY) and the FY2025 annual result came in at -$1.1 million, down 436.27% from the prior year.
• Change in Account Payables improved to $1.5 million in Q1 2026, from -$275228.0 in the prior quarter.
• In the past five years, Change in Account Payables ranged from a high of $1.5 million in Q1 2026 to a low of -$986841.0 in Q3 2022.
• A 5-year average of $9452.4 and a median of -$72739.0 in 2025 frame the typical range for Change in Account Payables.
• Annual changes were most pronounced in 2024 — Change in Account Payables slumped 4165.22% — and 2026, when it soared 251.37%.
• Tracing NERV's Change in Account Payables over 5 years: stood at $436779.0 in 2022, then fell by 6.07% to $410250.0 in 2023, then surged by 157.08% to $1.1 million in 2024, then tumbled by 126.1% to -$275228.0 in 2025, then soared by 632.31% to $1.5 million in 2026.
• The last three Change in Account Payables figures came in at $1.5 million (Q1 2026), -$275228.0 (Q4 2025), and -$72739.0 (Q3 2025), per Business Quant data.